Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Repare Therapeutics Inc. < Previous 1 2 Next > Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI June 26, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial June 10, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer June 04, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 May 29, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results May 07, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition April 30, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors April 26, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Participate in Two Upcoming Investor Conferences February 29, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results February 28, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 February 15, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Regain Global Rights to Camonsertib February 12, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment January 25, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones January 08, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer January 04, 2024 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans December 29, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor November 15, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results November 09, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast November 07, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Participate in Two Upcoming Investor Conferences November 06, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib October 13, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 03, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics September 19, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference September 06, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results August 09, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference June 08, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials June 07, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors June 06, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights June 02, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 22, 2023 From Repare Therapeutics Inc. Via Business Wire Tickers RPTX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.